Clinical TrialsThe CAHmelia-204 and CAHptain-205 clinical trials will be discontinued; the company plans to wind down its investment in tildacerfont for the treatment of CAH.
Market PerformanceShares of Spruce Biosciences were trading at approximately 37% of end-quarter cash before the news, and were down around 22% in the aftermarket.
Regulatory ApprovalTildacerfont faces an uncertain future at best, particularly in the wake of the recent U.S. regulatory approval of crinecerfont.